Idera Stops P-II (INTRIM 1) Trial of Tilsotolimod (IMO-2125) Due to Positive Efficacy in Patients with Melanoma
Shots:
- The company has stopped the patient enrollment early for its P-II (INTRIM 1) trial of tilsotolimod, after interim data delivered positive efficacy results. The trial was conducted by UMC Amsterdam
- The P-II (INTRIM 1) study evaluates tilsotolimod (8mg, ID) vs PBO in patients with pT3-4 cN0M0 melanoma, followed by re-excision & SLN biopsy after 7-10 days
- The interim results showed a lower SLN+ rate (70% vs 40%). This outcome demonstrates earlier results from the same trial which showed immune activation, including elevated frequencies of dendritic cells in early analysis by using flow cytometry of the SLN biopsies. The test seeks to confirm RFS & OS @ 5 & 10yrs. after SLN biopsy
Ref: Globenewswire | Image: Idera
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
